Why to Start Small on Healthcare IT By Munzoor Shaikh By limiting scope initially, providers can define a business case, derive insights and build momentum to tackle larger challenges.
What Should Prescriptions Cost? By Scott Martin The Anthem lawsuit against Express Scripts should raise a key question: Is my employer in the same boat as Anthem?
Flogging the Data Until It Confesses By Tom Emerick When you hear boasts of big short-term impacts of wellness programs, beware. Someone is likely flogging the data.
The Sorry Spectacle of Defensive Medicine By Erik Leander Richard Anderson As this infographic shows, as much as $850 billion a year is wasted on unnecessary, defensive medical tests and procedures in the U.S.
23 Questions on the Use of Narcotics By Mark Pew At some point, the evidence of death and destruction from our prescription drug abuse epidemic will overwhelm the lobbyists.
What New Delhi’s Free Clinics Can Teach U.S. By Vivek Wadhwa The Swasthya Slate, costing just $600 and no bigger than a cake tin, performs 33 common medical tests and can be operated with minimal training.
6 Limitations of Big Data in Healthcare By Tom Emerick David Toomey No. 5: Miscoding can render analysis meaningless -- one company didn't know it was paying for 25 organ transplants a year.
BPO for Life & Annuity Market By Paul Livak Bruce Brodie Paul Frank Growth is hard enough in today’s market; it’s harder when your back-office holds you back. Business process outsourcing (BPO) can help.
Auto Insurance in an Existential Crisis By Stephen Applebaum Alan Demers The 125-year-old, $300 billion U.S. auto insurance industry is caught between runaway inflation and strained consumer wallets.
The Promise of Continuous Underwriting By Bill Deemer Bobby Touran Typically, a risk is underwritten, bound... and forgotten. But new streams of data and automation allow for continuous underwriting.
Convergence and the Insurance Ecosystem By Stephen Applebaum Alan Demers Companies must anticipate the future, innovate beyond their core and transform their capabilities as rapidly as technology allows.
Lemonade's 'Synthetic Agent' Nonsense By Matteo Carbone Desperate for growth, Lemonade produces another howler: A lender receiving a 16% interest rate is presented as a (synthetic) agent.